Saxenda weight-loss injections now available via telehealth for eligible patients
Saxenda, an injectable weight-loss medication, is now available through several telehealth platforms. Approved by the FDA, the drug is prescribed after an online consultation with a healthcare professional. Patients must meet specific BMI criteria to qualify for treatment.
Saxenda (liraglutide) works similarly to Ozempic but is specifically designed for weight management. It is intended for adults with a BMI of 30 or higher, or 27 and above with weight-related conditions. Children aged 12 to 17 with a BMI of 30 or more may also be eligible.
Telehealth platforms have made Saxenda more accessible to eligible patients. Those considering the medication must consult a healthcare provider to assess suitability. Proper research into the service’s reliability and safety remains essential before starting treatment.
